If you are searching for serious, citeable evidence behind tesamorelin in the UAE, you have landed on the right page. REVIVE LAB UAE is the trusted peptides Dubai destination for researchers who want HPLC-tested vials, real references, and 24h delivery — not aesthetic forum guesswork. Today we unpack the two clinical trial pillars every tesamorelin protocol traces back to: Falutz 2007/2010 and Stanley 2014. By the end you will understand exactly why tesamorelin earned its visceral-fat reputation, what doses the trials used, and how to order tesamorelin in Dubai, Abu Dhabi, Sharjah or RAK with discreet packaging from REVIVE Peptides UAE.
HIV-associated lipodystrophy is a paradoxical syndrome: patients on long-term antiretroviral therapy develop massive truncal and visceral fat while losing subcutaneous fat in the limbs and face. The visceral adipose tissue (VAT) compartment ballooned in these cohorts, making them metabolically high-risk and — crucially for trial design — easy to measure with MRI. That made HIV lipodystrophy the cleanest possible model for testing a GHRH analog that restores pulsatile GH secretion and IGF-1 tone.
Tesamorelin (a 44-amino-acid trans-3-hexenoyl modified GHRH(1-44)) was engineered to resist DPP-IV degradation, giving it a half-life long enough for once-daily 2 mg subcutaneous injection. The hypothesis was simple: restore physiologic GH pulses, and VAT — the most GH-sensitive fat depot — will shrink. The Falutz and Stanley trials tested exactly that.
Theodoros Falutz and colleagues ran two of the largest tesamorelin trials in HIV patients with abdominal lipohypertrophy. Falutz et al. NEJM 2007 randomized 412 patients to tesamorelin 2 mg/day SC vs placebo for 26 weeks. The headline result: VAT fell by ~15.2% in the tesamorelin arm versus a +5% rise on placebo (p<0.001), with simultaneous improvements in triglycerides and the cholesterol-to-HDL ratio. Lean body mass was preserved.
Falutz et al. JCEM 2010 followed with extension data — the patients who continued tesamorelin held their VAT reduction, while those switched to placebo regained fat within 26 weeks. That dose-response durability finding is what cemented tesamorelin as a real GHRH analog rather than a transient endocrine trick. Every modern tesamorelin protocol — including the ones REVIVE Peptides UAE customers reference — uses the 2 mg/day SC anchor that Falutz validated.
| Trial | N | Dose | Duration | VAT change |
|---|---|---|---|---|
| Falutz 2007 (NEJM) | 412 | 2 mg SC daily | 26 weeks | −15.2% vs +5.0% placebo |
| Falutz 2010 (JCEM ext.) | 404 | 2 mg SC daily | 52 weeks | Durable −18% maintained |
| Stanley 2014 (JAMA) | 50 | 2 mg SC daily | 6 months | −15.7% VAT, −37% liver fat |
By 2014, Steven Grinspoon's MGH group — led by Takara Stanley — asked a sharper question: if tesamorelin shrinks VAT, does it also shrink the ectopic fat sitting inside the liver? HIV patients carry a brutal NAFLD burden, so the team enrolled 50 HIV patients with hepatic steatosis and randomized them to tesamorelin 2 mg SC daily vs placebo for 6 months (Stanley et al., JAMA 2014; follow-up Stanley et al., Lancet HIV 2019).
The result was striking: liver fat fraction dropped by an absolute 37% in the tesamorelin arm, with parallel reductions in hepatic inflammation markers and continued VAT loss. The 2019 follow-up extended this to NASH histology endpoints — fibrosis progression was reduced. For peptide researchers, Stanley 2014 is the citation that elevated tesamorelin from "cosmetic VAT drug" to a genuine metabolic intervention with reproducible MRI-PDFF readouts. It is also why serious UAE researchers stockpile REVIVE LAB UAE tesamorelin 5 mg and 10 mg vials rather than chasing newer untested analogs.
Tesamorelin binds the pituitary GHRH receptor and restores physiologic, pulsatile GH release. GH then drives hepatic IGF-1 synthesis. The GH/IGF-1 axis preferentially lipolyzes visceral and ectopic (liver) fat because those depots are GH-receptor-rich. Subcutaneous fat — much less GH-sensitive — is largely spared. That is the lean-mass preservation signature you see in every Falutz/Stanley dataset, and it is what makes tesamorelin distinct from semaglutide-class agents that bleed lean mass.
The vials REVIVE Peptides UAE ships across Dubai, Abu Dhabi, Sharjah, Ajman, RAK, Fujairah, Umm Al Quwain and Al Ain are calibrated to make the Falutz/Stanley dose easy to replicate in a research setting:
REVIVE Peptides UAE will only ever ship the strengths we actually carry. For tesamorelin that means 5 mg and 10 mg lyophilized vials — nothing else. We will never list a fictional "20 mg mega-vial" to win a click. That is the difference between a real peptides supplier UAE and a forum reseller.
Order before 2 PM and your tesamorelin ships same-day from our Dubai cold-chain hub. Typical delivery windows:
Tesamorelin cash on delivery UAE is available across all emirates. Discreet anonymous packaging is standard — plain outer box, no peptide branding, vial integrity protected by gel ice packs. This is what "trusted peptides UAE" actually looks like in 2026.
REVIVE LAB UAE is a Dubai-based research peptides supplier serving the United Arab Emirates research community. Every vial is HPLC-tested, lyophilized to research-grade purity, cold-chain shipped, and discreetly packaged. We hold tesamorelin 5 mg and 10 mg in stock at all times in the UAE — no overseas wait, no customs lottery. Browse all REVIVE Peptides UAE products or jump straight to the tesamorelin money page below.
REVIVE LAB UAE is the in-stock peptides Dubai source for tesamorelin 5 mg and 10 mg vials, with 24h delivery across Dubai, Abu Dhabi and Sharjah, and 24–48h to RAK, Fujairah and Al Ain. Cash on delivery and discreet packaging across the UAE.
Add BAC water 3 mL to the lyophilized 5 mg powder, swirl gently, refrigerate. On a 1 mL insulin syringe at 100 units = 1 mL, each unit = ~16.7 µg tesamorelin. The Falutz/Stanley 2 mg/day dose corresponds to ~12 units. Use a 29G or 31G needle for subcutaneous injection. Research use only.
HPLC certificate per batch, cold-chain courier, real UAE stock, real references (Falutz 2007/2010, Stanley 2014/2019 — all PubMed-citeable), and same-day Dubai dispatch. We never invent strengths or fabricate authors. That is why researchers across Jumeirah, Palm, DIFC and Abu Dhabi default to REVIVE Peptides UAE.